Amy Parison, Senior Vice President and Chief Financial Officer of Editas Medicine, Inc., filed a statement of changes in beneficial ownership on September 4, 2026, disclosing a sale of common stock that occurred on September 3, 2026.

Key Highlights

  • Reporting person: Amy Parison, SVP and Chief Financial Officer of Editas Medicine, Inc.
  • Transaction date: September 3, 2026, involving a sale (code "S") of 453 shares of common stock.
  • Sale price: 453 shares were disposed of at $3.0372 per share.
  • Post-transaction ownership: Parison directly held 13,839 shares of common stock following the transaction.
  • Plan-based sale: The sale was made pursuant to a durable automatic sales instruction plan adopted on July 7, 2022, and was not a discretionary trade by the reporting person.
  • Tax withholding purpose: The shares were sold by the issuer to meet tax withholding obligations arising from the vesting of restricted stock units on September 2, 2026.

Editas Medicine CFO Share Disposal Tied to RSU Vesting and Tax Withholding

According to the filing, Editas Medicine (NASDAQ:EDIT) CFO Amy Parison disposed of 453 shares of common stock on September 3, 2026, at a price of $3.0372 per share. The filing indicates this transaction was carried out under a durable automatic sales instruction plan that Parison adopted on July 7, 2022, which the filing characterizes as intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The filing explicitly states that "the sale does not represent a discretionary trade by the Reporting Person."

The filing further explains that the shares were sold by the issuer to cover tax withholding obligations connected to restricted stock units that vested on September 2, 2026. Editas Medicine is a genome editing company whose common stock trades on the NASDAQ exchange under the ticker EDIT. Following the reported transaction, Parison directly held 13,839 shares of Editas Medicine common stock. No derivative securities transactions were reported in Table II of the filing.

What Was Disclosed

The filing disclosed a single non-derivative transaction in which 453 shares of Editas Medicine common stock were sold at $3.0372 per share on September 3, 2026, under a pre-established Rule 10b5-1 plan, leaving the CFO with direct beneficial ownership of 13,839 shares.